Patents by Inventor Kenneth M. Wells

Kenneth M. Wells has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the preparation of compounds useful as inhibitors of SGLT-2
    Patent number: 9522931
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: December 20, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kenneth M. Wells, Ronald K. Russell, Xun Li, Shawn Branum, Derek A. Beauchamp, Sumihiro Nomura, Yosuke Matsumura
  • Sulfonamides as TRPM8 modulators
    Patent number: 9434711
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: September 6, 2016
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Shawn T Branum, Raymond W Colburn, Scott L Dax, Christopher M Flores, Michele C Jetter, Yi Liu, Donald Ludovici, Mark J Macielag, Jay M Matthews, James J McNally, Laura M Andraka, Ronald K Russell, Ning Qin, Christopher Teleha, Kenneth M Wells, Scott C Youells, Mark A Youngman
  • Process for the preparation of compounds useful as inhibitors of SGLT
    Patent number: 9024009
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: May 5, 2015
    Assignees: Janssen Pharmaceutica N.V., Mitsubishi Tanabe Pharma Corporation
    Inventors: Ahmed F. Abdel-Magid, Maureen Chislom, Steven Mehrman, Lorraine Scott, Kenneth M. Wells, Fan Zhang-Plasket, Sumihiro Nomura, Mitsuya Hongu, Yuichi Koga
  • SULFONAMIDES AS TRPM8 MODULATORS
    Publication number: 20140315899
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: Shawn T. Branum, Raymond W. Colburn, Scott L. Dax, Christopher M. Flores, Michele C. Jetter, Yi Liu, Donald Ludovici, Mark J. Macielag, Jay M. Matthews, James J. McNally, Laura M. Andraka, Ronald K. Russell, Ning Qin, Christopher Teleha, Kenneth M. Wells, Scott C. Youells, Mark A. Youngman
  • Crystalline hydrochloride salt of (1-(4-fluorophenyl)-1H-indol-5-yl)-(3-(4-(thiazole-2-carbonyl)piperazin-1-yl)azetidin-1-yl)methanone
    Patent number: 8835417
    Abstract: The present invention relates to a crystalline hydrochloride salt of (1-(4-fluorophenyl)-1H-indol-5-yl)(3-(4-(thiazole-2-carbonyl)piperazin-1-yl)azetidin-1-yl)methanone, methods of making said salt, pharmaceutical compositions containing said salt, and the use of said salt in the treatment of pain and diseases that cause such pain, and metabolic disorders such as, obesity, hyperphagia, and diabetes.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: September 16, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Derek A. Beauchamp, Kenneth M. Wells
  • Sulfonamides as TRPM8 modulators
    Patent number: 8809327
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: August 19, 2014
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Shawn T. Branum, Raymond W. Colburn, Scott L. Dax, Christopher M. Flores, Michele C. Jetter, Yi Liu, Donald Ludovici, Mark J. Macielag, Jay M. Matthews, James J. McNally, Laura M. Reaney, Ronald K. Russell, Ning Qin, Christopher Teleha, Kenneth M. Wells, Scott C. Youells, Mark A. Youngman
  • PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT-2
    Publication number: 20140206859
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Application
    Filed: May 18, 2012
    Publication date: July 24, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Kenneth M. Wells, Xun Li, Shawn Branum, Sumihiro Nomura, Yosuke Matsumura
  • PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT-2
    Publication number: 20140206858
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Application
    Filed: May 18, 2012
    Publication date: July 24, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Kenneth M. Wells, Ronald K. Russell, Xun Li, Shawn Branum, Derek A. Beauchamp, Sumihiro Nomura, Yosuke Matsumura
  • SULFONAMIDES AS TRPM8 MODULATORS
    Publication number: 20120190674
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.
    Type: Application
    Filed: February 28, 2012
    Publication date: July 26, 2012
    Inventors: Shawn T. Branum, Raymond W. Colburn, Scott L. Dax, Christopher M. Flores, Michele C. Jetter, Yi Liu, Donald Ludovici, Mark J. Macielag, Jay M. Matthews, James J. McNally, Laura M. Reaney, Ronald K. Russell, Ning Qin, Christopher Teleha, Kenneth M. Wells, Scott C. Youells, Mark A. Youngman
  • Sulfonamides as TRPM8 modulators
    Patent number: 8153682
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: April 10, 2012
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Shawn T. Branum, Raymond W. Colburn, Scott L. Dax, Christopher M. Flores, Michele C. Jetter, Yi Liu, Donald Ludovici, Mark J. Macielag, Jay M. Matthews, James J. McNally, Laura M. Reaney, Ronald K. Russell, Ning Qin, Christopher Teleha, Kenneth M. Wells, Scott C. Youells, Mark A. Youngman
  • BENZIMIDAZOLE MODULATORS OF VR1
    Publication number: 20110190364
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Application
    Filed: April 12, 2011
    Publication date: August 4, 2011
    Inventors: Mark R. Player, Scott L. Dax, William H. Parsons, Michael Richard Brandt, Raul R. Calvo, Sharmila Patel, Jian Liu, Wing S. Cheung, Michele C. Jetter, Yu-Kai Lee, Mark A. Youngman, Wenxi Pan, Kenneth M. Wells, Derek A. Beauchamp
  • BENZIMIDAZOLE MODULATORS OF VR1
    Publication number: 20110190344
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Application
    Filed: April 12, 2011
    Publication date: August 4, 2011
    Inventors: Mark R. Player, Scott L. Dax, William H. Parsons, Michael Richard Brandt, Raul R. Calvo, Sharmila Patel, Jian Liu, Wing S. Cheung, Michele C. Jetter, Yu-Kai Lee, Mark A. Youngman, Wenxi Pan, Kenneth M. Wells, Derek A. Beauchamp
  • Benzimidazole modulators of VR1
    Patent number: 7951829
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: May 31, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark R. Player, Scott L. Dax, William H. Parsons, Michael Richard Brandt, Raul R. Calvo, Sharmila Patel, Jian Liu, Wing S. Cheung, Michele C. Jetter, Yu-Kai Lee, Mark A. Youngman, Wenxi Pan, Kenneth M. Wells, Derek A. Beauchamp
  • CRYSTALLINE FORMS OF 4-[6-(6-METHANESULFONYL-2-METHYL-PYRIDIN-3-YLAMINO)-5-METHOXY-PYRIMIDIN-4-YLOXY]-PIPERIDINE-1-CARBOXYLIC ACID ISOPROPYL ESTER
    Publication number: 20110015215
    Abstract: The present invention is directed to a novel crystalline forms of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutical compositions containing said crystalline form and the use of said crystalline forms in the treatment of metabolic related disorders. The present invention is further directed to processes for the preparation of the crystalline forms of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester.
    Type: Application
    Filed: May 20, 2010
    Publication date: January 20, 2011
    Inventors: Paul Deghetto, Nagy E. Fawzy, Gary Fech, Kenneth M. Wells, Wenju Wu
  • SULFONAMIDES AS TRPM8 MODULATORS
    Publication number: 20090264474
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.
    Type: Application
    Filed: July 18, 2008
    Publication date: October 22, 2009
    Inventors: Shawn T. Branum, Raymond W. Colburn, Scott L. Dax, Christopher M. Flores, Michele C. Jetter, Yi Liu, Donald Ludovici, Mark J. Macielag, Jay M. Matthews, James J. McNally, Laura M. Reaney, Ronald K. Russell, Ning Qin, Christopher Teleha, Kenneth M. Wells, Scott C. Youells, Mark A. Youngman
  • PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT
    Publication number: 20090233874
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Application
    Filed: September 9, 2008
    Publication date: September 17, 2009
    Inventors: Ahmed F. Abdel-Magid, Maureen Chisholm, Steven Mehrman, Lorraine Scott, Kenneth M. Wells, Fan Zhang-Plasket, Sumihiro Nomura, Mitsuya Hongu, Yuichi Koga
  • Amine salts of an integrin receptor antagonist
    Patent number: 7074930
    Abstract: Amine salts of 3-{2-oxo-3-[3-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)-propyl]imidazolidin-1-yl}-3-(6-methoxy-pyridin-3-yl)propionic acid are potent antagonists of the integrin ?v?3 receptor and are useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salts as well as pharmaceutical compositions containing the salts and methods of using the salts.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: July 11, 2006
    Assignee: Merck & Co., Inc
    Inventors: Kenneth M. Wells, Nobuyoshi Yasuda, Yaling Wang
  • Amine salts of an integrin receptor antagonist
    Publication number: 20040249158
    Abstract: Amine salts of 3-{2-oxo-3-[3-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)-propyl]imidazolidin-1-yl}-3-(6-methoxy-pyridin-3-yl)propionic acid are potent antagonists of the integrin &agr;v&bgr;3 receptor and are useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salts as well as pharmaceutical compositions containing the salts and methods of using the salts.
    Type: Application
    Filed: May 3, 2004
    Publication date: December 9, 2004
    Inventors: Kenneth M Wells, Nobuyoshi Yasuda, Yaling Wang
  • Process and intermediates for the preparation of imidazolidinone &agr;v integrin antagonists
    Patent number: 6407241
    Abstract: A novel process is provided for the preparation of imidazolidinone &agr;v&bgr;3/&agr;v&bgr;5 integrin antagonists, and the useful intermediates obtained therein. These compounds are antagonists of &agr;v&bgr;3/&agr;v&bgr;5 integrin receptors and thus useful for inhibiting bone resorption and treating and preventing osteoporosis. Also disclosed is 3-{2-oxo-3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]imidazolidin-1-yl}-3(S)-(6-methoxy-pyridin-3-yl)-propionic acid in the form of a hemihydrate.
    Type: Grant
    Filed: November 7, 2000
    Date of Patent: June 18, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Mark S Jensen, Michael Palucki, Nelo R. Rivera, Kenneth M. Wells, Yi Xiao, Yaling Wang, Chunhua Yang, Nobuyoshi Yasuda
  • Crystalline 2-hydroxymethyl carbapenem intermediate compounds and process for synthesis thereof
    Patent number: 6346617
    Abstract: A process for preparation of a compound of formula I: wherein: R1 represents CH3 or H; and P represents a protecting group; comprising reacting a compound of formula IV:  wherein R1 and P and are defined above and R4 represents triflate or SO2F; in the presence of a catalyst and (R3)3SnCH2OP″, wherein each R3 represents C1-4 lower alkyl, and P″ represents H or a protecting group, to yield the compound of formula I.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: February 12, 2002
    Assignee: Merck & Co., Inc.
    Inventors: John Y. Chung, Nobuyoshi Yasuda, Johnnie L. Leazer, Jr., Mark S. Jensen, Kenneth M. Wells, Chunhua Yang